5-Chlorobenzotriazole | CAS:94-97-3

We serve 5-Chlorobenzotriazole CAS:94-97-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-Chlorobenzotriazole

Chemical Name:5-Chlorobenzotriazole
CAS.NO:94-97-3
Synonyms:5-Chlorobenzotriazole
5-Chloro-1,2,3-benzotriazole
1H-Benzotriazole,5-chloro
5-chloro-1h-benzotriazol
Molecular Formula:C6H4ClN3
Molecular Weight:153.56900
 
Physical and Chemical Properties:
Density:1.531
Melting point:157-159ºC
Boiling point:315.5ºC
Flash point:173.9ºC
Index of Refraction:1.696
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Applicationd as a plating additive



Contact us for information like 5-Chlorobenzotriazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-chloro-1h-benzotriazol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Chlorobenzotriazole Use and application,1H-Benzotriazole,5-chloro technical grade,usp/ep/jp grade.


Related News: Countries and territories that have confirmed cases: Thailand, Japan, Hong Kong, Singapore, Taiwan, Australia, Malaysia, Macau, Russia, France, the United States, South Korea, Germany, the United Arab Emirates, Canada, Britain, Vietnam, Italy, India, the Philippines, Nepal, Cambodia, Sri Lanka, Finland, Sweden and Spain.1,3-Dibromo-2-propanol manufacturer Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.benzyl (3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate,hydrochloride supplier Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.Lithium Trifluoromethanesulfonate vendor Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.Here’s what Apple told CNN Business in a statement: